全文获取类型
收费全文 | 7928篇 |
免费 | 400篇 |
国内免费 | 80篇 |
专业分类
耳鼻咽喉 | 53篇 |
儿科学 | 62篇 |
妇产科学 | 41篇 |
基础医学 | 1394篇 |
口腔科学 | 105篇 |
临床医学 | 492篇 |
内科学 | 1462篇 |
皮肤病学 | 20篇 |
神经病学 | 835篇 |
特种医学 | 306篇 |
外科学 | 465篇 |
综合类 | 345篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 874篇 |
眼科学 | 62篇 |
药学 | 1394篇 |
5篇 | |
中国医学 | 98篇 |
肿瘤学 | 393篇 |
出版年
2025年 | 2篇 |
2024年 | 108篇 |
2023年 | 155篇 |
2022年 | 358篇 |
2021年 | 484篇 |
2020年 | 334篇 |
2019年 | 410篇 |
2018年 | 375篇 |
2017年 | 305篇 |
2016年 | 255篇 |
2015年 | 303篇 |
2014年 | 441篇 |
2013年 | 673篇 |
2012年 | 391篇 |
2011年 | 462篇 |
2010年 | 323篇 |
2009年 | 382篇 |
2008年 | 406篇 |
2007年 | 337篇 |
2006年 | 247篇 |
2005年 | 238篇 |
2004年 | 191篇 |
2003年 | 183篇 |
2002年 | 159篇 |
2001年 | 118篇 |
2000年 | 103篇 |
1999年 | 79篇 |
1998年 | 75篇 |
1997年 | 99篇 |
1996年 | 69篇 |
1995年 | 57篇 |
1994年 | 55篇 |
1993年 | 33篇 |
1992年 | 25篇 |
1991年 | 24篇 |
1990年 | 24篇 |
1989年 | 29篇 |
1988年 | 10篇 |
1987年 | 12篇 |
1986年 | 13篇 |
1985年 | 17篇 |
1984年 | 10篇 |
1983年 | 6篇 |
1982年 | 5篇 |
1981年 | 4篇 |
1980年 | 5篇 |
1979年 | 5篇 |
1978年 | 3篇 |
1977年 | 2篇 |
1976年 | 4篇 |
排序方式: 共有8408条查询结果,搜索用时 31 毫秒
101.
102.
Pamela P. Pei Milton C. Weinstein X. Cynthia Li Michael D. Hughes A. David Paltiel Taige Hou 《HIV clinical trials》2015,16(6):207-218
Value of Information (VOI) analysis examines whether to acquire information before making a decision. We introduced VOI to the HIV audience, using the example of generic antiretroviral therapy (ART) in the US.Methods and Findings:We used a mathematical model and probabilistic sensitivity analysis (PSA) to generate probability distributions of survival (in quality-adjusted life years, QALYs) and cost for three potential first-line ART regimens: three-pill generic, two-pill generic, and single-pill branded. These served as input for a comparison of two hypothetical two-arm trials: three-pill generic versus single-pill branded; and two-pill generic versus single-pill branded. We modeled pre-trial uncertainty by defining probability distributions around key inputs, including 24-week HIV-RNA suppression and subsequent ART failure. We assumed that, without a trial, patients received the single-pill branded strategy. Post-trial, we assumed that patients received the most cost-effective strategy. For both trials, we quantified the probability of changing to a generic-based regimen upon trial completion and the expected VOI in terms of improved health outcomes and costs. Assuming a willingness to pay (WTP) threshold of $100?000/QALY, the three-pill trial led to more treatment changes (84%) than the two-pill trial (78%). Estimated VOI was $48?000 (three-pill trial) and $35?700 (two-pill trial) per future patient initiating ART.Conclusions:A three-pill trial of generic ART is more likely to lead to post-trial treatment changes and to provide more value than a two-pill trial if policy decisions are based on cost-effectiveness. Value of Information analysis can identify trials likely to confer the greatest impact and value for HIV care. 相似文献
103.
ObjectiveData in electronic health records (EHRs) is being increasingly leveraged for secondary uses, ranging from biomedical association studies to comparative effectiveness. To perform studies at scale and transfer knowledge from one institution to another in a meaningful way, we need to harmonize the phenotypes in such systems. Traditionally, this has been accomplished through expert specification of phenotypes via standardized terminologies, such as billing codes. However, this approach may be biased by the experience and expectations of the experts, as well as the vocabulary used to describe such patients. The goal of this work is to develop a data-driven strategy to (1) infer phenotypic topics within patient populations and (2) assess the degree to which such topics facilitate a mapping across populations in disparate healthcare systems.MethodsWe adapt a generative topic modeling strategy, based on latent Dirichlet allocation, to infer phenotypic topics. We utilize a variance analysis to assess the projection of a patient population from one healthcare system onto the topics learned from another system. The consistency of learned phenotypic topics was evaluated using (1) the similarity of topics, (2) the stability of a patient population across topics, and (3) the transferability of a topic across sites. We evaluated our approaches using four months of inpatient data from two geographically distinct healthcare systems: (1) Northwestern Memorial Hospital (NMH) and (2) Vanderbilt University Medical Center (VUMC).ResultsThe method learned 25 phenotypic topics from each healthcare system. The average cosine similarity between matched topics across the two sites was 0.39, a remarkably high value given the very high dimensionality of the feature space. The average stability of VUMC and NMH patients across the topics of two sites was 0.988 and 0.812, respectively, as measured by the Pearson correlation coefficient. Also the VUMC and NMH topics have smaller variance of characterizing patient population of two sites than standard clinical terminologies (e.g., ICD9), suggesting they may be more reliably transferred across hospital systems.ConclusionsPhenotypic topics learned from EHR data can be more stable and transferable than billing codes for characterizing the general status of a patient population. This suggests that EHR-based research may be able to leverage such phenotypic topics as variables when pooling patient populations in predictive models. 相似文献
104.
Triantafyllos Stylianopoulos Rakesh K. Jain 《Proceedings of the National Academy of Sciences of the United States of America》2013,110(46):18632-18637
Blood perfusion in tumors can be significantly lower than that in the surrounding normal tissue owing to the leakiness and/or compression of tumor blood vessels. Impaired perfusion reduces oxygen supply and results in a hypoxic microenvironment. Hypoxia promotes tumor progression and immunosuppression, and enhances the invasive and metastatic potential of cancer cells. Furthermore, poor perfusion lowers the delivery of systemically administered drugs. Therapeutic strategies to improve perfusion include reduction in vascular permeability by vascular normalization and vascular decompression by alleviating physical forces (solid stress) inside tumors. Both strategies have shown promise, but guidelines on how to use these strategies optimally are lacking. To this end, we developed a mathematical model to guide the optimal use of these strategies. The model accounts for vascular, transvascular, and interstitial fluid and drug transport as well as the diameter and permeability of tumor vessels. Model simulations reveal an optimal perfusion region when vessels are uncompressed, but not very leaky. Within this region, intratumoral distribution of drugs is optimized, particularly for drugs 10 nm in diameter or smaller and of low binding affinity. Therefore, treatments should modify vessel diameter and/or permeability such that perfusion is optimal. Vascular normalization is more effective for hyperpermeable but largely uncompressed vessels (e.g., glioblastomas), whereas solid stress alleviation is more beneficial for compressed but less-permeable vessels (e.g., pancreatic ductal adenocarcinomas). In the case of tumors with hyperpermeable and compressed vessels (e.g., subset of mammary carcinomas), the two strategies need to be combined for improved treatment outcomes.Perfused vessels are necessary for enabling adequate oxygenation and distribution of systemically administered drugs in solid tumors. However, perfusion rates in some regions of a tumor can be significantly lower than that in the peritumor normal tissue, leading to hypoxia, low pH, and inadequate drug delivery. Impaired blood perfusion in tumors could result from (i) excessive fluid loss from the vasculature to the interstitial space owing to vessel hyperpermeability (Fig. 1A), (ii) increased resistance to fluid flow caused by vessel tortuosity, and (iii) reduced effective cross-sectional area for blood flow due to vessel compression (Fig. 1C) (1, 2). Vessel hyperpermeability and tortuosity can be lowered using judicious doses of antiangiogenic agents (1, 3–6). Fig. 1 A and B shows a schematic of how vascular normalization can improve perfusion by improving the structure and composition of the vessel wall, and Open in a separate windowFig. 1.Schematic of therapeutic strategies to improve tumor perfusion. (A) Abnormalities in interendothelial junctions, pericyte coverage, and/or basement membrane lead to hyperpermeability of tumor blood vessels and excessive fluid leakage that slows down blood flow. (B) Vascular normalization fortifies the vessel wall, resulting in smaller interendothelial gaps (“pores”) and improved perfusion. (C) Structural components of the tumor microenvironment exert forces on blood vessels, resulting in vessel compression and reduced blood flow. (D) Alleviation of these forces by selective depletion of tumor constituents (e.g., cells or extracellular matrix) can decompress the vessels and improve vessel perfusion. BM, basement membrane; CC, cancer and/or stromal cell; EC, endothelial cell; ECM, extracellular matrix; PC, pericyte.
Open in a separate windowInformation given in the table is updated from ref. 5. FTI, farnesyltransferase inhibitors; GBM, glioblastoma multiforme; PHD2, prolyl hydroxylase domain protein 2; TKI, tyrosine kinase inhibitor; VE-PTP, vascular endothelial protein tyrosine phosphatase.*Clinical evidence.Vessel compression is a result of physical forces—referred to as solid stress—accumulated within solid components of tumors (cancer and stromal cells, collagen, and hyaluronan) (23–25). Stress alleviation can be achieved by depletion of any or all of these components, which can reopen compressed vessels and improve perfusion and delivery of drugs (25, 26). The schematic in Fig. 1 C and D shows how depletion of cancer or stromal cells can decompress blood vessels, and Therapeutic agent Target Tumor model Effect on vessel diameter/density (refs.) Effect on perfusion (refs.) Diptheria toxin Cancer cells Soft tissue sarcoma ↑ (24) Not reported Taxane Cancer cells Soft tissue sarcoma ↑ (23) Not reported Saridegib Stromal cells Pancreatic ductal carcinoma ↑ (25, 27) ↑ (25, 27) PEGPH20 Hyaluronan Pancreatic ductal carcinoma ↑ (28, 29) ↑ (28, 29) 1D11 Collagen Mammary carcinoma ↑ (30) ↑ (30) Losartan Stromal cells, hyaluronan, collagen Pancreatic ductal carcinoma ↑ (26) ↑ (26)
Table 1.
Studies showing vascular normalization improves perfusion measured as improved oxygenationTherapeutic agent | Tumor model | Effect on oxygenation (refs.) |
Antibody | ||
Bevacizumab | Melanoma, breast and ovarian carcinomas, GBM | ↑ (7, 8) |
DC101 | GBM, mammary carcinoma | ↑ (9, 10) |
TKI | ||
Cediranib | GBM | ↑ (11–13)* |
Sunitinib | Squamous carcinoma | ↑ (14) |
Semaxanib | Melanoma | ↑ (15) |
Other therapies | ||
PI-103 (PI3K inhibitor) | Fibrosarcoma, squamous carcinoma | ↑ (16) |
FTIs (Ras inhibitors) | Prostate carcinoma, bladder carcinoma, glioma, fibrosarcoma, squamous carcinoma | ↑ (16–18) |
Nelfinavir (AKT inhibitor) | Fibrosarcoma, squamous carcinoma | ↑ (16) |
PHD2 down-regulation | Lung carcinomas | ↑ (19) |
R-Ras up-regulation | Melanomas and lung carcinomas | ↑ (20) |
Cancer cells nitric oxide synthesis inhibition | Glioblastomas | ↑ (21) |
VE-PTP inhibition | Breast carcinomas | ↑ (22) |